Cabotamig is under clinical development by Arbele and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) ...
(MENAFN- GlobeNewsWire - Nasdaq) This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape. Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback